Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 40 years of age or older
- People who have been diagnosed with either Smoldering Multiple Myeloma or a Monoclonal Gammopathy (two conditions involving abnormal proteins in the blood)
- People whose dFLC level (a measurement of certain proteins in the blood called free light chains) is greater than 23 mg/L
- People who have an abnormal FLC ratio (another measurement related to these proteins in the blood)
- People with reduced kidney function (eGFR below 50 mL/min/1.73m²) may still be considered eligible based on age and dFLC level alone, without needing to meet the FLC ratio criterion (confirm with trial site)
Who may not be able to join:
- People under the age of 40
- People who have previously had amyloid (an abnormal protein deposit) found in any biopsy result
- People who are not able to give their own informed consent to participate, including those with cognitive impairment
- People who are pregnant
- People who are minors (under the age of legal adulthood)
- People who are wards of the state
- People who are prisoners
- Neonates (newborns), including those who are non-viable or of uncertain viability
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-636-6454
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Creating a network to enroll patients on a collaborative study requiring marrow and blood specimens, to collect data for a training set of likelihood statistics and to plan a future validation study.; Validating an NGS assay that identifies IGLV genes in clonal plasma cells
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.